Wentzel-Larsen T - Search Results

1

Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer.

Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Bjøro T, Wentzel-Larsen T, Dahl O; Norwegian Urology Cancer Group (NUCG) III study group. Brydøy M, et al. Br J Cancer. 2012 Nov 20;107(11):1833-9. doi: 10.1038/bjc.2012.471. Br J Cancer. 2012. PMID: 23169336 Free PMC article.

2

Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.

Karlsdóttir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O. Karlsdóttir A, et al. Radiother Oncol. 2004 Apr;71(1):43-53. doi: 10.1016/j.radonc.2004.01.014. Radiother Oncol. 2004. PMID: 15066295

3

Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers.

Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Larsen A, et al. Scand J Gastroenterol. 2004 Nov;39(11):1113-8. doi: 10.1080/00365520410003614. Scand J Gastroenterol. 2004. PMID: 15545170

4

Testing the new ICRU 62 'Planning Organ at Risk Volume' concept for the rectum.

Muren LP, Karlsdottir A, Kvinnsland Y, Wentzel-Larsen T, Dahl O. Muren LP, et al. Radiother Oncol. 2005 Jun;75(3):293-302. doi: 10.1016/j.radonc.2005.03.007. Radiother Oncol. 2005. PMID: 15878630

5

Paternity following treatment for testicular cancer.

Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O. Brydøy M, et al. J Natl Cancer Inst. 2005 Nov 2;97(21):1580-8. doi: 10.1093/jnci/dji339. J Natl Cancer Inst. 2005. PMID: 16264178

6

Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer.

Karlsdottir A, Muren PL, Wentzel-Larsen T, Johannessen DC, Bakke A, Ogreid P, Halvorsen OJ, Dahl O. Karlsdottir A, et al. Acta Oncol. 2006;45(4):454-62. doi: 10.1080/02841860500468943. Acta Oncol. 2006. PMID: 16760182

7

Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin.

Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen EK, Fagerhol MK. Larsen A, et al. Scand J Immunol. 2007 Feb;65(2):192-201. doi: 10.1111/j.1365-3083.2006.01875.x. Scand J Immunol. 2007. PMID: 17257225 Free article.

8

Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy.

Larsen A, Bjørge B, Klementsen B, Helgeland L, Wentzel-Larsen T, Fagerhol MK, Hovdenak N, Dahl O. Larsen A, et al. Acta Oncol. 2007;46(5):639-50. doi: 10.1080/02841860601099241. Acta Oncol. 2007. PMID: 17562440

9

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.

Sørbye H, Berglund A, Tveit KM, Ogreid D, Wanderås EH, Wentzel-Larsen T, Dahl O, Glimelius B. Sørbye H, et al. Acta Oncol. 2007;46(7):982-8. doi: 10.1080/02841860701261568. Acta Oncol. 2007. PMID: 17917829 Clinical Trial.

10

Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.

Karlsdóttir A, Muren LP, Wentzel-Larsen T, Dahl O. Karlsdóttir A, et al. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1478-86. doi: 10.1016/j.ijrobp.2007.08.076. Epub 2007 Dec 3. Int J Radiat Oncol Biol Phys. 2008. PMID: 18060703

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters